17:56 , Apr 28, 2017 |  BC Week In Review  |  Company News

Epigenomics, Cathay Fortune deal

Cathay's Blitz F16-83 GmbH subsidiary will acquire molecular diagnostics company Epigenomics for €7.52 per share, or about €171 million ($185.6 million) in cash. The price is a 52% premium on Epigenomics' closing price of €4.95...
22:38 , Apr 26, 2017 |  BC Extra  |  Company News

Chinese PE firm to acquire Epigenomics

A subsidiary of Chinese private equity firm Cathay Fortune International Co. Ltd. will acquire molecular diagnostics company Epigenomics AG (Xetra:ECX; OTCQX:EPGNY) for €7.52 per share, or about €171 million ($185.6 million) in cash. The subsidiary,...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Company News

Epigenomics, BioChain Institute deal

Epigenomics granted BioChain exclusive Chinese rights to develop and commercialize Epigenomics’ blood-based lung cancer test. Epigenomics will receive an undisclosed upfront payment and is eligible for milestone and minimum annual payments, plus mid-single-digit royalties. The...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Epigenomics, BioChain Institute sales and marketing update

Epigenomics said the Chinese Guideline on Screening, Endoscopic Diagnosis and Treatment of Early Colorectal Cancer (CRC) recommended plasma Septin9 gene DNA methylation assay (mSEPT9) as a standard test for early CRC screening. Epi proColon, a...
07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

Epi proColon: Clinical trial data

The U.S. ADMIT trial in 413 average-risk patients ages 50-76 who have been historically non-compliant to colorectal cancer screening according to screening guidelines showed a 99.5% rate of adherence to colorectal cancer screening using Epigenomics’...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Epi proColon: Clinical trial completed enrollment

Epigenomics completed enrollment of about 420 average-risk patients ages 50-76 that have been historically non-compliant to colorectal cancer screening according to screening guidelines in the U.S. ADMIT trial comparing Epi proColon vs. fecal immunochemical test...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Clinical News

Epi proColon: Clinical trial started

Epigenomics began the U.S. ADMIT trial to compare Epi proColon vs. fecal immunochemical test (FIT) in about 420 average-risk patients ages 50-76 years that have been historically non-compliant to colorectal cancer screening according to screening...
08:00 , Jan 5, 2015 |  BioCentury  |  Finance

4Q14 Stock Wrap-up: Grow early, grow often

Biotech stocks rose in 4Q14, with only the microcaps segment, with valuations under $200 million, finishing down. The rally followed two quarters in which only the large cap segment, with valuations over $5 billion, were...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Clinical News

Epi proColon 2 regulatory update

BioChain and Epigenomics said the China Food and Drug Administration (CFDA) approved Epi proColon 2.0 blood-based colorectal cancer screening test. BioChain plans to launch the test in the country “within the next weeks.” BioChain has...
04:04 , Dec 9, 2014 |  BC Extra  |  Company News

China approves Epigenomics' colon cancer test

Epigenomics AG (Xetra:ECX; OTCQX:EPGNY) jumped EUR 1.03 (23%) to EUR 5.53 on Monday after China FDA approved the company's Epi proColon 2.0 non-invasive, blood-based diagnostic test for colorectal cancer. Epigenomics said partner BioChain Institute Inc....